Cargando…
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
PURPOSE: Medullary Thyroid Cancer (MTC) whose pathogenesis is strictly related to RET proto-oncogene alterations, has been shown to have a heterogenic RET mutation profile in subpopulations of MTC. The aim of our study was to investigate the RET somatic mutation profile in primary MTC and in the cor...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839408/ https://www.ncbi.nlm.nih.gov/pubmed/29515777 http://dx.doi.org/10.18632/oncotarget.23986 |
_version_ | 1783304405469102080 |
---|---|
author | Romei, Cristina Ciampi, Raffaele Casella, Francesca Tacito, Alessia Torregrossa, Liborio Ugolini, Clara Basolo, Fulvio Materazzi, Gabriele Vitti, Paolo Elisei, Rossella |
author_facet | Romei, Cristina Ciampi, Raffaele Casella, Francesca Tacito, Alessia Torregrossa, Liborio Ugolini, Clara Basolo, Fulvio Materazzi, Gabriele Vitti, Paolo Elisei, Rossella |
author_sort | Romei, Cristina |
collection | PubMed |
description | PURPOSE: Medullary Thyroid Cancer (MTC) whose pathogenesis is strictly related to RET proto-oncogene alterations, has been shown to have a heterogenic RET mutation profile in subpopulations of MTC. The aim of our study was to investigate the RET somatic mutation profile in primary MTC and in the corresponding metastatic tissues in a series of advanced metastatic cases. RESULTS: This study demonstrated that in about 20% of cases a different RET mutation profile can be found when comparing primary tumor and its corresponding metastases. Furthermore in 8% of tumors, RET intratumor heterogeneity was observed We also showed that in some cases an imbalance of RET copy number was present. We confirmed a high prevalence (90%) of RET somatic mutations in advanced tumors. MATERIALS AND METHODS: Fifty-six MTC patients (50 somatic and 6 hereditary cases) have been included in the study and a total of 209 specimens have been analysed by direct sequencing. Multiplex ligation-dependent probe amplification (MLPA) has been used to investigate amplification/deletion of RET alleles. CONCLUSIONS: In conclusion, this study showed a genetic intra- and intertumor heterogeneity in MTC, But in only 20% of CASES These results could justify the relatively moderate level of aggressiveness of the disease with respect to more aggressive human tumors that are characterized by a high rate of mutation and heterogeneity. |
format | Online Article Text |
id | pubmed-5839408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-58394082018-03-07 RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases Romei, Cristina Ciampi, Raffaele Casella, Francesca Tacito, Alessia Torregrossa, Liborio Ugolini, Clara Basolo, Fulvio Materazzi, Gabriele Vitti, Paolo Elisei, Rossella Oncotarget Research Paper PURPOSE: Medullary Thyroid Cancer (MTC) whose pathogenesis is strictly related to RET proto-oncogene alterations, has been shown to have a heterogenic RET mutation profile in subpopulations of MTC. The aim of our study was to investigate the RET somatic mutation profile in primary MTC and in the corresponding metastatic tissues in a series of advanced metastatic cases. RESULTS: This study demonstrated that in about 20% of cases a different RET mutation profile can be found when comparing primary tumor and its corresponding metastases. Furthermore in 8% of tumors, RET intratumor heterogeneity was observed We also showed that in some cases an imbalance of RET copy number was present. We confirmed a high prevalence (90%) of RET somatic mutations in advanced tumors. MATERIALS AND METHODS: Fifty-six MTC patients (50 somatic and 6 hereditary cases) have been included in the study and a total of 209 specimens have been analysed by direct sequencing. Multiplex ligation-dependent probe amplification (MLPA) has been used to investigate amplification/deletion of RET alleles. CONCLUSIONS: In conclusion, this study showed a genetic intra- and intertumor heterogeneity in MTC, But in only 20% of CASES These results could justify the relatively moderate level of aggressiveness of the disease with respect to more aggressive human tumors that are characterized by a high rate of mutation and heterogeneity. Impact Journals LLC 2018-01-04 /pmc/articles/PMC5839408/ /pubmed/29515777 http://dx.doi.org/10.18632/oncotarget.23986 Text en Copyright: © 2018 Romei et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Romei, Cristina Ciampi, Raffaele Casella, Francesca Tacito, Alessia Torregrossa, Liborio Ugolini, Clara Basolo, Fulvio Materazzi, Gabriele Vitti, Paolo Elisei, Rossella RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases |
title | RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases |
title_full | RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases |
title_fullStr | RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases |
title_full_unstemmed | RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases |
title_short | RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases |
title_sort | ret mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839408/ https://www.ncbi.nlm.nih.gov/pubmed/29515777 http://dx.doi.org/10.18632/oncotarget.23986 |
work_keys_str_mv | AT romeicristina retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT ciampiraffaele retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT casellafrancesca retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT tacitoalessia retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT torregrossaliborio retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT ugoliniclara retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT basolofulvio retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT materazzigabriele retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT vittipaolo retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases AT eliseirossella retmutationheterogeneityinprimaryadvancedmedullarythyroidcancersandtheirmetastases |